Metagenomi Therapeutics, Inc. (MGX) Q1 2024 Earnings
MGX·Reported May 14, 2024·Before market open
Metagenomi Therapeutics, Inc. reported Q1 2024 revenue of $11.2M, beat analyst consensus of $7.9M by $3.3M. Diluted EPS came in at $-1.19, missed the $-0.95 consensus by $0.24.
Revenue
$11.2Mbeat by $3.3M
Consensus: $7.9MDiluted EPS
$-1.19missed by $0.24
Consensus: $-0.95
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Metagenomi Therapeutics, Inc. 's Q1 2024 earnings report.
Metagenomi Therapeutics, Inc. (MGX) reported Q1 2024 earnings on May 14, 2024 before market open.
Metagenomi Therapeutics, Inc. reported revenue of $11.2M and diluted EPS of $-1.19 for Q1 2024.
Revenue beat the consensus estimate of $7.9M by $3.3M. EPS missed the consensus estimate of $-0.95 by $0.24.
You can read the 10-Q periodic report (0000950170-24-059504) directly on SEC EDGAR. The filing index links above go to sec.gov.